These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17912634)

  • 1. Letrozole in the neoadjuvant setting: the P024 trial.
    Ellis MJ; Ma C
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letrozole in the extended adjuvant setting: MA.17.
    Goss PE
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):45-53. PubMed ID: 17912635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
    Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
    Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
    Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
    Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and mechanism of action of letrozole.
    Bhatnagar AS
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):7-17. PubMed ID: 17912633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
    ; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS
    N Engl J Med; 2009 Aug; 361(8):766-76. PubMed ID: 19692688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
    Dickler M
    Nat Clin Pract Oncol; 2005 Oct; 2(10):498-9. PubMed ID: 16205767
    [No Abstract]   [Full Text] [Related]  

  • 19. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
    Smith IE
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):289-93. PubMed ID: 14623523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.